低慢性暴露于PFOS可选择性地激活Aβ清除途径,以改善AD小鼠的认知能力
Haijing Zhang1, Chao Zhang2, Qin Wang1
1China CDC Key Laboratory of Environment and Population Health, National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing, 100021, China.
Environmental pollution (Barking, Essex : 1987)
|October 25, 2024
概括
低慢性暴露在 perfluorooctane sulfonate (PFOS) 中令人惊地缓解了阿尔茨海默病 (AD) 的小鼠的认知障碍. 这种效应与通过胰岛素降解酶 (IDE) 上调增强的粉样β清除有关.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- perfluorooctane sulfonate (PFOS) 是一种持久性有机污染物,对认知有争议的影响.
- 以前的研究将PFOS暴露与神经元亡和正常小鼠的认知衰退联系在一起.
- 阿尔茨海默病 (AD) 的特点是认知障碍和粉样β (Aβ) 积累.
研究的目的:
- 研究亚慢性PFOS暴露对阿尔茨海默病小鼠模型认知障碍的影响.
- 阐明潜在的分子机制,特别是胰岛素降解酶 (IDE) 和神经炎症的作用.
主要方法:
- 在AD模型小鼠中,对PFOS的亚慢性暴露.
- 使用行为测试评估认知功能.
- 在前额叶皮质 (PFC) 中测量胰岛素降解酶 (IDE) 表达水平.
- 粉样β (Aβ) 生产和清除的分析.
- 在PFC中评估微质增殖和炎症性细胞因子水平.
主要成果:
- 在AD小鼠中,次慢性PFOS暴露显著降低了认知障碍.
- 暴露于PFOS上调了PFC中的IDE表达,增强了Aβ清除而不影响Aβ产生.
- 在AD小鼠的PFC中,PFOS抑制了微质增殖,降低了AD小鼠的炎症性细胞因子水平.
- 这些发现表明PFOS在AD病理学中通过IDE介导的机制起着保护作用.
结论:
- 在亚慢性PFOS暴露缓解认知障碍,并延缓阿尔茨海默氏病病鼠的疾病进展.
- 胰岛素降解酶 (IDE) 介导的粉样β清除途径是PFOS有益作用的关键机制.
- PFOS可能调节神经炎症和微质活性,有助于其在AD病理学中的保护作用.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.粉样蛋白-β (Aβ) 是一种认知功能 认知功能暴露 暴露 暴露降解胰岛素的酶可以降解胰岛素.perfluorooctane 硫酸盐 (PFOS) 是一种含有的化合物.更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.1K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.2K
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
